New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
10:55 EDTAMGN, AMGN, NVS, NVS, MRK, MRK, INCY, INCY, GSK, GSK, EXEL, EXEL, BMY, BMY, AZN, AZN, ARRY, ARRY, RHHBY, RHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts Liang and Kapur discuss the market opportunity and role of immunotherapy in the adjuvant melanoma setting ahead of the upcoming ASCO Annual Meeting on an Analyst/Industry conference call. Relevant companies AMGN, ARRY, AZN, BMY, EXEL, GSK, INCY, MRK, NVS and RHHBY may be discussed on the Analyst/Industry conference call to be held on May 28 at 11:30 am.
News For AMGN;ARRY;AZN;BMY;EXEL;GSK;INCY;MRK;NVS;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 23, 2015
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
07:23 EDTGSK, AZN, BMY, RHHBYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSK, NVS, MRK, AZNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTRHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
10:32 EDTEXELHigh option volume stocks:
Subscribe for More Information
09:12 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTRHHBYLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
08:23 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
07:12 EDTNVSWharton Health Care Club to hold a conference
Subscribe for More Information
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
05:31 EDTEXEL, RHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information
February 18, 2015
08:13 EDTINCYIncyte shares poised to rise further, says Argus
Subscribe for More Information
February 17, 2015
18:17 EDTAMGNJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
17:16 EDTAZNActavis confirms temporary injunction related to generic Pulmicort RESPULES
Subscribe for More Information
10:01 EDTAMGNCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
08:01 EDTINCYIncyte price target raised to $90 from $80 at Leerink
Leerink raised its price target for Incyte shares to $90 citing the company's growing oncology pipeline following its Q4 results. The firm keeps an Outperform rating on the name.
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use